Novartis pays big premium to get hands on AveXis in $8.7 billion deal

Novartis plans to buy AveXis for $218 per share in a $8.7 billion cash deal, adding a therapy hopeful for spinal muscular atrophy (SMA) to the Swiss drugmaker's pipeline that is expected to reap billions in annual sales. from Novartis pays big premium to get hands on AveXis in $8.7 billion deal via Novartis pays big premium to get hands on AveXis in $8.7 billion deal April 09, 2018 at 01:12AM   copyright 2018 from Novartis pays big premium to get hands on AveXis in $8.7 billion deal via Novartis pays big premium to get hands on AveXis in $8.7 billion deal July 23, 2018 at 12:11PM Philadelphia, Pennsylvania Consumer Credit Counseling